| Dr Laure G Demattia, DO | |
|
2821 36th Ave Nw Ste 200, Norman, OK 73072-2477 | |
| (405) 515-2049 | |
| (405) 307-5630 |
| Full Name | Dr Laure G Demattia |
|---|---|
| Gender | Female |
| Speciality | Family Practice |
| Experience | 24 Years |
| Location | 2821 36th Ave Nw Ste 200, Norman, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1235181579 | NPI | - | NPPES |
| 006906261I | Other | HUMANA | |
| 43508500 | Medicaid | WI |
| Facility Name | Location | Facility Type |
|---|---|---|
| Norman Regional | Norman, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Norman Regional Providers Primary Care | 5496837718 | 51 |
News Archive
NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced new results from a combined analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Trans-Arimidex, Tamoxifen, Alone or in Combination (TransATAC) studies. These results, which evaluated samples from 2,137 patients, suggest that the PAM50-based Prosignaz Breast Cancer Prognostic Gene Signature Assay may help identify women with late distant recurrence after five years of endocrine treatment.
Today Biogen Idec released the primary efficacy analysis and safety data from its Phase 3 pivotal clinical trial, ADVANCE.
In anticipation of World Tuberculosis (TB) Day, commemorated on March 24, this Lancet editorial examines TB control and elimination efforts in 2012 and beyond. "Tuberculosis killed 1.45 million people in 2010 and about 500,000 people have drug-resistant disease," the editorial states, adding, "Despite a woeful funding gap in 2012 of $1.7 billion, tuberculosis incidence is falling (from 9.4 million in 2009 to 8.8 million in 2010)."
AFFiRiS announced today the results of a phase II study in Alzheimer patients. AFFiRiS' proprietary compound AD04 is the first drug ever to demonstrate clinical and biomarker effects consistent with disease modification in Alzheimer patients.
› Verified 7 days ago
| Entity Name | Norman Regional Providers Primary Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548398274 PECOS PAC ID: 5496837718 Enrollment ID: O20080125000271 |
News Archive
NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced new results from a combined analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Trans-Arimidex, Tamoxifen, Alone or in Combination (TransATAC) studies. These results, which evaluated samples from 2,137 patients, suggest that the PAM50-based Prosignaz Breast Cancer Prognostic Gene Signature Assay may help identify women with late distant recurrence after five years of endocrine treatment.
Today Biogen Idec released the primary efficacy analysis and safety data from its Phase 3 pivotal clinical trial, ADVANCE.
In anticipation of World Tuberculosis (TB) Day, commemorated on March 24, this Lancet editorial examines TB control and elimination efforts in 2012 and beyond. "Tuberculosis killed 1.45 million people in 2010 and about 500,000 people have drug-resistant disease," the editorial states, adding, "Despite a woeful funding gap in 2012 of $1.7 billion, tuberculosis incidence is falling (from 9.4 million in 2009 to 8.8 million in 2010)."
AFFiRiS announced today the results of a phase II study in Alzheimer patients. AFFiRiS' proprietary compound AD04 is the first drug ever to demonstrate clinical and biomarker effects consistent with disease modification in Alzheimer patients.
› Verified 7 days ago
| Entity Name | Norman Regional Providers Specialty Care |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548513773 PECOS PAC ID: 5496900706 Enrollment ID: O20130312000200 |
News Archive
NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced new results from a combined analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Trans-Arimidex, Tamoxifen, Alone or in Combination (TransATAC) studies. These results, which evaluated samples from 2,137 patients, suggest that the PAM50-based Prosignaz Breast Cancer Prognostic Gene Signature Assay may help identify women with late distant recurrence after five years of endocrine treatment.
Today Biogen Idec released the primary efficacy analysis and safety data from its Phase 3 pivotal clinical trial, ADVANCE.
In anticipation of World Tuberculosis (TB) Day, commemorated on March 24, this Lancet editorial examines TB control and elimination efforts in 2012 and beyond. "Tuberculosis killed 1.45 million people in 2010 and about 500,000 people have drug-resistant disease," the editorial states, adding, "Despite a woeful funding gap in 2012 of $1.7 billion, tuberculosis incidence is falling (from 9.4 million in 2009 to 8.8 million in 2010)."
AFFiRiS announced today the results of a phase II study in Alzheimer patients. AFFiRiS' proprietary compound AD04 is the first drug ever to demonstrate clinical and biomarker effects consistent with disease modification in Alzheimer patients.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Laure G Demattia, DO Po Box 1330, Norman, OK 73070-1330 Ph: (405) 735-2049 | Dr Laure G Demattia, DO 2821 36th Ave Nw Ste 200, Norman, OK 73072-2477 Ph: (405) 515-2049 |
News Archive
NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced new results from a combined analysis of the Austrian Breast & Colorectal Cancer Study Group 8 (ABCSG-8) and Trans-Arimidex, Tamoxifen, Alone or in Combination (TransATAC) studies. These results, which evaluated samples from 2,137 patients, suggest that the PAM50-based Prosignaz Breast Cancer Prognostic Gene Signature Assay may help identify women with late distant recurrence after five years of endocrine treatment.
Today Biogen Idec released the primary efficacy analysis and safety data from its Phase 3 pivotal clinical trial, ADVANCE.
In anticipation of World Tuberculosis (TB) Day, commemorated on March 24, this Lancet editorial examines TB control and elimination efforts in 2012 and beyond. "Tuberculosis killed 1.45 million people in 2010 and about 500,000 people have drug-resistant disease," the editorial states, adding, "Despite a woeful funding gap in 2012 of $1.7 billion, tuberculosis incidence is falling (from 9.4 million in 2009 to 8.8 million in 2010)."
AFFiRiS announced today the results of a phase II study in Alzheimer patients. AFFiRiS' proprietary compound AD04 is the first drug ever to demonstrate clinical and biomarker effects consistent with disease modification in Alzheimer patients.
› Verified 7 days ago
Ms. Kathleen E Lewis, MD Family Medicine Medicare: Not Enrolled in Medicare Practice Location: 1300 Mcgee Dr, Ste 100, Norman, OK 73072 Phone: 405-321-0406 Fax: 405-447-6293 | |
Jayson D Henry, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 500 E Robinson St, Suite 2200, Norman, OK 73071 Phone: 405-515-0380 Fax: 405-928-2054 | |
Dr. Hieu Chi Nguyen, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 700 24th Ave Nw, Norman, OK 73069 Phone: 405-364-0555 Fax: 405-573-5464 | |
Kevin Q Epperson, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3400 W Tecumseh Rd, Suite 104, Norman, OK 73072 Phone: 405-515-1800 Fax: 405-515-1805 | |
Bobby L Elliott, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 700 24th Ave Nw, Norman, OK 73069 Phone: 405-573-5400 Fax: 405-573-5406 | |
Dr. Aaron Michael Smathers, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 3400 W Tecumseh Rd Ste 101, Norman, OK 73072 Phone: 405-515-0649 Fax: 405-360-6769 | |
Michelle Deann Barnes, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 950 N Porter Ave, Suite 300, Norman, OK 73071 Phone: 405-329-0121 Fax: 405-292-6099 |